Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven D Nathan

Showing results (241-250 of 297) with videos related to

Pageof 30
Sort By:
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 16, 2023
Organizing pneumonia is associated with molecular allograft injury and the development of antibody-mediated rejectionMichael B Keller, Xin Tian, Moon Kyoo Jang, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|June 28, 2025
Impact of donor specific antibodies on longitudinal lung function and baseline lung allograft dysfunctionMuhtadi Alnababteh, Junfeng Sun, Rohan Meda, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 5, 2024
Extreme elevations of donor-derived cell-free DNA increases the risk of chronic lung allograft dysfunction and death, even without clinical manifestations of diseaseMichael B Keller, David Newman, Muhtadi Alnababteh, et al.
The Lancet. Respiratory Medicine|November 24, 2016
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosisSteven D Nathan, Carlo Albera, Williamson Z Bradford, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|February 10, 2022
WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertensionLaurent Savale, Marloes Huitema, Oksana Shlobin, et al.
Chest|April 10, 2015
Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary FibrosisDavid J Lederer, Williamson Z Bradford, Elizabeth A Fagan, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2009
Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanismsSouheil El-Chemaly, Daniela Malide, Enrique Zudaire, et al.
The European Respiratory Journal|August 8, 2015
Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restrictionGanesh Raghu, Steven D Nathan, Juergen Behr, et al.
Critical Care Explorations|April 23, 2025
Surfactant Protein D and Club Cell Secretory Protein as Biomarkers of Disease Severity and Fostamatinib Efficacy in Severe COVID-19Marcos J Ramos-Benitez, Rui Miao, Andrea P Rivera-Torres, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 22, 2025
Molecular criteria for pulmonary antibody-mediated rejection are associated with an increased risk of allograft failureMichael B Keller, David Newman, Muhtadi Alnababteh, et al.
Pageof 30

Showing results (241-250 of 297) with videos related to

Sort By:
Pageof 30
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|November 16, 2023
Organizing pneumonia is associated with molecular allograft injury and the development of antibody-mediated rejectionMichael B Keller, Xin Tian, Moon Kyoo Jang, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|June 28, 2025
Impact of donor specific antibodies on longitudinal lung function and baseline lung allograft dysfunctionMuhtadi Alnababteh, Junfeng Sun, Rohan Meda, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|May 5, 2024
Extreme elevations of donor-derived cell-free DNA increases the risk of chronic lung allograft dysfunction and death, even without clinical manifestations of diseaseMichael B Keller, David Newman, Muhtadi Alnababteh, et al.
The Lancet. Respiratory Medicine|November 24, 2016
Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosisSteven D Nathan, Carlo Albera, Williamson Z Bradford, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|February 10, 2022
WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertensionLaurent Savale, Marloes Huitema, Oksana Shlobin, et al.
Chest|April 10, 2015
Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary FibrosisDavid J Lederer, Williamson Z Bradford, Elizabeth A Fagan, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2009
Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanismsSouheil El-Chemaly, Daniela Malide, Enrique Zudaire, et al.
The European Respiratory Journal|August 8, 2015
Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restrictionGanesh Raghu, Steven D Nathan, Juergen Behr, et al.
Critical Care Explorations|April 23, 2025
Surfactant Protein D and Club Cell Secretory Protein as Biomarkers of Disease Severity and Fostamatinib Efficacy in Severe COVID-19Marcos J Ramos-Benitez, Rui Miao, Andrea P Rivera-Torres, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|March 22, 2025
Molecular criteria for pulmonary antibody-mediated rejection are associated with an increased risk of allograft failureMichael B Keller, David Newman, Muhtadi Alnababteh, et al.
Pageof 30